Trevi Therapeutics, Inc.
TRVI
Rank in Stocks
#5632
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused... Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Share Price
$15.31
Last synced: 2026-11-09
Market Cap
$2.18B
Change (1 day)
6.84%
Change (1 year)
26.53%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Trevi Therapeutics, Inc. (TRVI)
Category
Healthcare
EPS for Trevi Therapeutics, Inc. (TRVI)
EPS as of June 2026 TTM: $-0.34
According to Trevi Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.34. At the end of 2025 the company had an EPS of $-0.29, an increase over its 2024 EPS of $-0.47.
EPS history for Trevi Therapeutics, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.34 | 17.24% |
| 2025 | $-0.29 | -38.30% |
| 2024 | $-0.47 | 62.07% |
| 2023 | $-0.29 | -35.56% |
| 2022 | $-0.45 | -69.80% |
| 2021 | $-1.49 | -17.68% |
| 2020 | $-1.81 | 23.97% |
| 2019 | $-1.46 | -36.24% |
| 2018 | $-2.29 | 60.14% |
| 2017 | $-1.43 | 107.25% |
| 2016 | $-0.69 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -4,705.88% |
US
|
|
| $-7.07 | 1,979.41% |
US
|
|
| $-5.29 | 1,455.88% |
AU
|
|
| $12.88 | -3,888.26% |
BE
|
|
| $21.56 | -6,441.18% |
NL
|
Questions about Trevi Therapeutics, Inc.'s earnings per share (EPS)
What is Trevi Therapeutics, Inc.'s earnings per share (EPS)?
Trevi Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.34, as of Jun 2026.
What was Trevi Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Trevi Therapeutics, Inc.'s earnings per share (EPS) was $-0.29, compared with $-0.47 in 2024.
How has Trevi Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Trevi Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.29) and lowest in 2020 ($-1.81).
How does Trevi Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Trevi Therapeutics, Inc.'s earnings per share (EPS) ($-0.34) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.